Key points are not available for this paper at this time.
The monitoring and reporting of adverse drug reactions (ADRs) through pharmacovigilance is vital to patient safety and rational prescribing. In India, Central Drugs Standard Control Organization (CDSCO) initiated Pharmacovigilance Programme of India (PvPI) to report ADRs through ADRs monitoring centres in India. Indian Pharmacopoeia Commission (IPC) is functioning as National Coordination Centre (NCC) for PvPI. The ADRs are reported to NCC through VigiFlow by various centres are evaluated and committed to Uppsala Monitoring Centre, Sweden. The potential benefit of the PvPI is aimed to reducing or eliminating a harm of medicine. Continuous efforts of the healthcare professionals and the patients are expected to make this as one of the most successful and effective programmes. The present article updates the status and future plan of PvPI.
Kalaiselvan et al. (Sun,) studied this question.